Free tool
FAERS Monitor: Besponsa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761040 or its brand name (Besponsa, Inotuzumab Ozogamicin). Reports on generic versions are filed under their own applications.
Reports
2,992
Serious
2,854
95% of reports
Hospitalization
1,193
Death reported
1,018
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death360
- febrile neutropenia267
- venoocclusive liver disease260
- off label use232
- pyrexia198
- neoplasm progression155
- thrombocytopenia154
- acute lymphocytic leukaemia recurrent148
- drug ineffective143
- cytokine release syndrome142
- sepsis138
- venoocclusive disease132
- neutropenia122
- platelet count decreased121
- infection96
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 5 |
| 2009 | 4 |
| 2010 | 13 |
| 2011 | 13 |
| 2012 | 29 |
| 2013 | 29 |
| 2014 | 64 |
| 2015 | 71 |
| 2016 | 78 |
| 2017 | 77 |
| 2018 | 245 |
| 2019 | 251 |
| 2020 | 255 |
| 2021 | 368 |
| 2022 | 365 |
| 2023 | 350 |
| 2024 | 343 |
| 2025 | 254 |
| 2026 | 177 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,167 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute lymphocytic leukaemia recurrentSignal | 148 | 427.6 | 363.7 | 58,991 |
| venoocclusive diseaseSignal | 132 | 391.2 | 329.5 | 48,306 |
| venoocclusive liver diseaseSignal | 260 | 390.6 | 346.6 | 95,383 |
| cytokine release syndromeSignal | 142 | 50.1 | 42.7 | 6,744 |
| neoplasm progressionSignal | 155 | 31.5 | 27.0 | 4,531 |
| febrile neutropeniaSignal | 267 | 28.4 | 25.3 | 7,026 |
| thrombocytopeniaSignal | 154 | 9.7 | 8.3 | 1,197 |
| sepsisSignal | 138 | 8.7 | 7.4 | 937 |
| platelet count decreasedSignal | 121 | 8.0 | 6.7 | 736 |
| neutropeniaSignal | 122 | 6.3 | 5.3 | 543 |
| infectionSignal | 96 | 4.7 | 3.8 | 274 |
| pyrexiaSignal | 198 | 4.0 | 3.5 | 454 |
| deathSignal | 360 | 2.9 | 2.7 | 478 |
| off label use | 232 | 1.9 | 1.6 | 96 |
| drug ineffective | 143 | 0.8 | 0.6 | 11 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.